Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
This document assesses the risk to human health posed by a multi-country foodborne outbreak of Shiga toxin-producing Escherichia coli (STEC) infections associated with haemolytic uraemic syndrome taking place in the European Union (EU).
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
This document is an update of the EFSA/ECDC joint rapid risk assessment of 29 June and aims to add new information to this and earlier initial rapid risk assessments (27 May and 14 June 2011).
An update of the initial rapid risk assessment on the outbreak of E. Coli in Germany, prepared at the request of the European Commission, first published on 27 May 2011.
Shiga toxin-producing E. coli (STEC) is a group of pathogenic Escherichia coli strains capable of producing Shiga toxins, with the potential to cause severe enteric and systemic disease in humans.
At the request of the European Commission’s Directorate-General for Health and Consumers, a rapid risk assessment has been prepared concerning the outbreak of E Coli in Germany.